As of June 30 cash and cash equivalents totaled $18.8M. “Data publications and presentations continue to highlight the benefits of both our lead asset, Oxylanthanum Carbonate, or OLC, and UNI-494 targeting treatment for patients with life threatening kidney diseases,” said Shalabh Gupta, CEO of Unicycive. “For OLC, we expect to gain alignment with the FDA in the Fall of this year around the additional data requirements to advance the program towards submission of a New Drug Application. As we reported last month, recently published data demonstrated that OLC has the potential to improve medication adherence and the quality of life for patients suffering from chronic kidney disease. This reinforces our commitment to bring this important new treatment option to patients as soon as possible.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on UNCY:
- Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
- Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
- Unicycive announces publication of results on oxylanthanum carbonate
- Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
- Unicycive Therapeutics files to sell 111.02M shares of common stock for holders